As a board-certified obesity medicine physician practicing in Bluffton, SC, I’ve witnessed both personally and firsthand the transformative effects of GLP-1 receptor agonists injections, like tirzepatide, on patients battling obesity and its associated health conditions. These medications, including the recently FDA-approved Zepbound, are proving to be groundbreaking tools not just for weight loss but also for improving overall health and longevity.
The SURMOUNT-4 phase 3 clinical trial, led by researchers at Weill Cornell Medicine and NewYork-Presbyterian, highlights the profound long-term benefits of these medications. Participants who remained on tirzepatide for an additional year after the initial treatment phase experienced continued weight loss and maintained significant improvements in metabolic and cardiovascular health. Conversely, those who discontinued the medication regained much of the lost weight, along with a reversal of some health improvements.